Viking Therapeutics Inc (VKTX · NASDAQ)
VKTX · MARKET VIEW
Market view · as of Jun 1, 2026
Revenue (TTM)
$0
0.0% YoY
EPS (latest q)
$-1.37
vs $-0.91 est · miss
52-wk position
43.1%
-25.7% vs 52w high · +4.2% 1mo
Price (last ~year)
Viking Therapeutics (VKTX) reported a $164.1 million operating loss for the quarter ended March 31, 2026, as it continues to fund late-stage development of its VK2735 obesity drug candidate. The company, which currently holds a $3.80 billion market capitalization, has generated no revenue and missed analyst earnings estimates in each of the last four quarters. With $118.1 million in cash and no debt, the firm remains focused on its clinical-stage pipeline.
Valuation
- Market cap
- $3.80B
- PEG
- -0.03
- P/B
- 7.32
- EV/EBITDA
- -71.64
- Beta
- 0.71
- Analyst target
- $92.58
Quality & returns
- Operating margin
- 0.0%
- Profit margin
- 0.0%
- ROE
- -70.0%
- ROA
- -42.5%
Price movement
- Last
- $31.27
- 1-month
- +4.2%
- 3-month
- -0.8%
- RSI (14)
- 48
- vs SMA200
- -3.6%
- 52-wk position
- 43.1% -25.7% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-03-31 | $0 | $-164.1M | $-158.3M | $-164.1M |
| 2025-12-31 | $0 | $-164.7M | $-157.7M | $-164.7M |
| 2025-09-30 | $0 | $-98.6M | $-90.8M | $-98.4M |
| 2025-06-30 | $0 | $-74.6M | $-65.6M | $-74.5M |
Recent news
- Neutral Viking Therapeutics (VKTX) Misses Q1 Earnings as VK2735 R&D Surges Into Late-Stage Obesity Trials · 2026-06-01
- Neutral A Look At Viking Therapeutics (VKTX) Valuation As VK2735 Fuels Obesity Prospects And M&A Speculation · 2026-05-29
- Bullish Lake Street initiates coverage of Viking Therapeutics (VKTX) with buy recommendation · 2026-05-29
- Bullish Lake Street Initiates Viking Therapeutics With Buy Rating, $89 Price Target · 2026-05-28
- Bullish Lake Street initiates Viking Therapeutic stock with buy rating By Investing.com · 2026-05-28
- Bullish Viking Therapeutics (VKTX) Initiated with a Buy at Truist Financial · 2026-05-28
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)